+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


EMEA (Europe, Middle East & Africa) Substance Abuse Treatment Market - Growth, Trends, and Forecast (2019 - 2024)

  • ID: 4787456
  • Report
  • June 2019
  • Region: Europe, Middle East, Africa
  • 73 pages
  • Mordor Intelligence
until Jun 30th 2020
1 of 4

Enquire about COVID-19 updates for this product.

Enquire Now


  • Alkermes Plc
  • Allergan
  • Mallinckrodt LLC
  • Mylan Laboratories
  • Pfizer Inc
  • MORE
Market Overview

EMEA (Europe, Middle East & Africa) Substance Abuse Treatment Market is expected to witness a CAGR of 9.0% over the forecast period. Certain factors that are driving the market growth include rising drug awareness campaigns and prevention programs, a high number of addicted population, technological advancement in the diagnostics industry.

The rise in the drug awareness campaigns and associated prevention programs is one of the primary factors linked to the growth of the substance abuse treatment market in the EMEA region. It includes rising patient awareness, higher treatment seeking rate with increased government intervention, and encouragement to curb substance abuse in several countries. Medications that help avoid relapse and control drug cravings also propel this market. Additionally, an increasing number of treatment centers that have collaborations with private recovery facilities are entering the market, thus helping in the expansion of treatment access to a higher number of people in society. Furthermore, other factors, such as a high number of addicted population and technological advancement in the diagnostics industry, are transforming and driving this market.

However, the discontinuation of behavioral therapies often leads to a relapse of addiction, which is a crucial factor hindering the growth of this market. Many patients opt for outpatient care for the treatment of drug dependence. In addition, the high reluctance of individuals for accessing treatment modalities and poor treatment compliance in some countries hinder the growth of the market studied.

Scope of the Report

Substance abuse refers to the use of psychoactive substances, including illicit drugs, tobacco, and alcohol. Excessive use of a psychoactive substance can lead to major health and social issues, which in some cases can even lead to critical ailments and death.

Key Market Trends

Nicotine Replacement Treatment is Expected to Hold Significant Market Share in the Tobacco/Nicotine Addiction Treatment Segment

The nicotine in tobacco leads to actual physical dependence. This can cause unpleasant withdrawal symptoms when a person tries to quit. Nicotine replacement therapy (NRT) gives nicotine in the form of gum, patches, sprays, inhalers, or lozenges, which does not have other harmful chemicals in tobacco. Nicotine gum has been in use for around 30 years to help smokers quit smoking. Many studies have shown using nicotine gums; further, any other nicotine replacement therapy can nearly double the chances of quitting smoking. Europe has the highest prevalence of tobacco smoking among adults (28%) and some of the highest prevalence of tobacco use by adolescents. While tobacco use was previously largely a male phenomenon, the gap in prevalence between male and female adults is now very small (< 5%) in countries, such as Denmark, Ireland, the Netherlands, Norway, Sweden, and the United Kingdom. Products, such as Nicotex (Nicotine chewing gums), are available as OTC products and are widely used by people who actively want to quit smoking. Individuals smoking 20 or more cigarettes a day should use the 4 mg Nicotex gum, which needs to be prescribed by a physician. Individuals smoking 20 or fewer cigarettes a day should use the 2 mg Nicotex gum. Nicotine gums are much safer when compared to smoking, though they too have few side effects as any other drug, but bring together all the factors that benefit, which out power; there is a bright future for these gums in the upcoming years.

Competitive Landscape

The EMEA (Europe, Middle East & Africa) Substance Abuse Treatment market is highly competitive and consists of a number of major players. Companies like Alkermes Plc, Allergan, GSK PLC, Mallinckrodt LLC, Mylan Laboratories, Pfizer Inc, Purdue Pharma LP, Sanofi Aventis SA, Teva Pharmaceuticals, among others, hold the substantial market share in the Substance Abuse Treatment market.
Note: Product cover images may vary from those shown
2 of 4


  • Alkermes Plc
  • Allergan
  • Mallinckrodt LLC
  • Mylan Laboratories
  • Pfizer Inc
  • MORE
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study



4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Drug Awareness Campaigns and Prevention Programs
4.2.2 High Number of Addicted Population
4.2.3 Technological Advancement in the Diagnostics Industry
4.3 Market Restraints
4.3.1 Reluctance of Individuals for Accessing Treatment and Discontinuation of the Behavioral Therapies
4.3.2 Poor Treatment Compliance in Some Countries
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5.1 Abuse Type
5.1.1 Alcohol Dependence
5.1.2 Tobacco/Nicotine Addiction
5.1.3 Opioid Addiction
5.1.4 Other Abuse Types
5.2 Treatment
5.2.1 Alcohol Addiction Treatment
5.2.2 Tobacco/Nicotine Addiction Treatment Nicotine Replacement Treatment Non-Nicotine Medication Other Tobacco/Nicotine Addiction Treatments
5.2.3 Drug Abuse Treatment
5.2.4 Other Treatment Types
5.3 Distribution Channel
5.3.1 Hospital Pharmacies
5.3.2 Retail Pharmacies
5.3.3 Others
5.4 Geography
5.4.1 Europe Germany UK France Italy Spain Rest of Europe
5.4.2 Middle East and Africa GCC South Africa Rest of Middle East and Africa

6.1 Company Profiles
6.1.1 Alkermes Plc
6.1.2 Allergan
6.1.3 GSK PLC
6.1.4 Mallinckrodt LLC
6.1.5 Mylan Laboratories
6.1.6 Pfizer Inc
6.1.7 Purdue Pharma LP
6.1.8 Sanofi Aventis SA
6.1.9 Teva Pharmaceuticals

Note: Product cover images may vary from those shown
3 of 4


4 of 4
  • Alkermes Plc
  • Allergan
  • Mallinckrodt LLC
  • Mylan Laboratories
  • Pfizer Inc
  • Purdue Pharma LP
  • Sanofi Aventis SA
  • Teva Pharmaceuticals
Note: Product cover images may vary from those shown